Although surgery (surgical repair or replacement) is indicated for severe primary MR, about 50% of patients are considered too high risk to be suitable for surgery because of their age and/or comorbidities (1, 2) . This has paved the way for the development of catheter-based interventions to correct MR percutaneously. The MitraClip system (Abbott Vascular, Menlo Park, California) is the only technique that has been evaluated for transcatheter organic MR repair so far, providing a therapeutic alternative to open heart surgery. Although less effective in reducing the degree of MR, the MitraClip was proved to be safer than surgery in EVEREST II (Endovascular Valve Edge-to-Edge Repair Study) (3, 4) .
Because residual MR after MitraClip placement is associated with suboptimal outcomes and increases mortality, the goal of the procedure is to reduce MR as much as possible, so that implantation of multiple clips is often needed (3). Nevertheless, multiple clip implantation is associated with a reduction of the mitral valve opening area and an increase in the transmitral pressure gradient. Hence, the goal is to define an acceptable compromise between residual MR and transmitral gradient. Indeed, it has been demonstrated that both mitral stenosis and MR after MitraClip therapy have a negative impact on the long-term clinical outcomes of treated patients (5, 6) . Transesophageal echocardiography and color Doppler are the only tools to assess both residual MR and transmitral gradient, but accurate echocardiographic evaluations are limited by operator dependence and the fact that the analysis of a double-orifice valve is challenging (7, 8) . Indeed, the native mitral orifice is reduced and divided into 2 or more separate orifices with often eccentric residual jets (9) (10) (11) . Hemodynamic parameters could be helpful to guide MC therapy. Intraprocedural assessment of left atrial pressure (LAP) has been described as a helpful tool during MitraClip implantation (12, 13) . Eleid et al. 
